Industry
Medical - Instruments & Supplies
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Loading...
Open
2.46
Mkt cap
103M
Volume
215K
High
2.46
P/E Ratio
-9.44
52-wk high
5.56
Low
2.30
Div yield
N/A
52-wk low
2.30
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 12:38 pm
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 12:08 pm
Portfolio Pulse from Benzinga Insights
November 06, 2023 | 7:02 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2023 | 12:58 pm
Portfolio Pulse from Benzinga Insights
August 30, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2023 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2023 | 11:20 am
Portfolio Pulse from Benzinga Insights
August 07, 2023 | 9:01 pm
Portfolio Pulse from richadhand@benzinga.com
June 22, 2023 | 12:24 pm
Portfolio Pulse from Charles Gross
June 22, 2023 | 11:57 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.